PureTech Health PLC PureTech Health Appoints Atul Pande as CMO
February 23 2017 - 2:02AM
RNS Non-Regulatory
TIDMPRTC
PureTech Health PLC
23 February 2017
23 February 2017
PureTech Health plc
PureTech Health Appoints Atul Pande M.D., Former SVP at
GlaxoSmithKline, as Chief Medical Officer
PureTech Health plc ("PureTech" or the "Company", LSE: PRTC), a
cross-disciplinary biopharmaceutical company, today announced the
appointment of Atul Pande, M.D., as the Company's Chief Medical
Officer. In this new role, Dr. Pande will oversee all clinical
operations across PureTech Health's pipeline and work closely with
the team to de-risk and advance opportunities that hold the most
potential for patients.
Dr. Pande commented: "I am proud and delighted to join this
stellar team and hope to be instrumental in enabling the launch of
some of the truly innovative medicines in the PureTech Health
pipeline. Having been involved in clinical research and development
for more than twenty years, I believe that the PureTech Health
approach - which starts with ground-breaking science and signals of
human efficacy and stresses safety - has important advantages."
"We are excited to work more closely with Atul and to have
access to his drug development expertise across PureTech Health's
pipeline," said Daphne Zohar, Chief Executive Officer of PureTech
Health. "Atul is a seasoned drug development veteran who will help
to shepherd our advancing pipeline through mid- and late-stage
clinical trials while ensuring that synergies are leveraged across
our platforms."
Dr. Pande has more than two decades of experience in drug
development. He is the former Senior Vice President, Head of
Neuroscience, and Senior Advisor, Pharmaceutical R&D at
GlaxoSmithKline. Dr. Pande has been active in the development of
multiple investigational and now marketed drugs while holding
various senior roles in Pfizer R&D, Parke-Davis/Warner-Lambert,
and Lilly Research Laboratories. His experience includes drug
development, registration, launch and lifecycle management in the
areas of anxiety, depression, epilepsy, neuropathic pain,
schizophrenia, traumatic brain injury, and Alzheimer's and
Parkinson's diseases. Dr. Pande is a psychiatrist and fellow of
several scientific societies, including the American Psychiatric
Association. He currently serves on the Board of Directors of
PureTech's Karuna Pharmaceuticals. He also sits on the Board of
Axovant Sciences (NYSE:AXON), and Autifony Therapeutics and on the
Scientific Advisory Board of Cennerv Pharma. Dr. Pande began his
career as a faculty member at the University of Michigan Medical
School where his research focused on mood disorders. He has
published over 50 peer-reviewed scientific papers and over 100
abstracts, book chapters, and book reviews.
About PureTech Health
PureTech Health (PureTech Health plc, PRTC.L) is a
cross-disciplinary biopharmaceutical company creating 21(st)
century medicines that modulate the adaptive human systems. Our
therapies target the immune, nervous, and gastro-intestinal systems
by addressing the underlying pathophysiology of disease from a
systems perspective rather than through a single receptor or
pathway. We have multiple human proof-of-concept studies and
pivotal or registration studies expected to read out in the next
two years. PureTech Health's rich and growing research and
development pipeline has been developed in collaboration with some
of the world's leading scientific experts who, along with
PureTech's experienced team and board, analyse more than 650
scientific discoveries per year to identify and advance only the
opportunities we believe hold the most promise for patients. This
team and process place PureTech Health on the cutting edge of
ground-breaking science and technological innovation and leads the
Company between and beyond existing disciplines. For more
information, visit www.puretechhealth.com or connect with us on
Twitter.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
For further information:
Media: PureTech Health FTI Consulting
Allison Mead Ben Atwell
+1 617 651 3156 +44 (0) 20 3727
amead@puretechhealth.com 1000
Investors: Graham Morrell
+1 617 986 1659
gm@puretechhealth.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUUSARBSAUUUR
(END) Dow Jones Newswires
February 23, 2017 02:02 ET (07:02 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024